Delayed administration of allogeneic cardiac stem cell therapy for acute myocardial infarction could ameliorate adverse remodeling: Experimental study in swine

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Crisostomo, Veronica ^a   Baez Diaz, Claudia ^a   Maestre, Juan ^a   Garcia Lindo, Monica ^a   Sun, Fei ^a   Casado, Javier G ^a   Blazquez, Rebeca ^a   Abad, Jose L ^b   Palacios, Itziar ^b   Rodriguez Borlado, Luis ^b   Sanchez Margallo, Francisco M ^a  

^a JESÚS USÓN MINIMALLY INVASIVE SURGERY CENTRE   (Spain)

^b Santiago Grisolía ^*  (Spain)

Author keywords

Allogeneic; Cardiac remodeling; Cardiac stem cells; Experimental; Myocardial infarction

Indexed keywords

TROPONIN I; TROPONIN;

ACUTE HEART INFARCTION; ALLOGENEIC CARDIAC STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY SURFACE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR SYSTEM EXAMINATION; COLLAGENOUS CAR; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY OCCLUSION; ELECTROCARDIOGRAPHY; EXPERIMENTAL STUDY; FEMALE; HEART EJECTION FRACTION; HEART FUNCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART VENTRICLE REMODELING; HEART VENTRICLE VOLUME; HISTOPATHOLOGY; INTRACORONARY DRUG ADMINISTRATION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; PIG; REPERFUSION INJURY; SAFETY; SCAR; ST SEGMENT ELEVATION; THERAPY DELAY; THROMBOLYSIS IN MYOCARDIAL INFARCTION SCALE; ALLOTRANSPLANTATION; ANIMAL; CARDIAC MUSCLE CELL; CYTOLOGY; HEART FUNCTION TEST; HEART VENTRICLE; HUMAN; METABOLISM; MYOCARDIAL INFARCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PERICARDIAL EFFUSION; STEM CELL; STEM CELL TRANSPLANTATION; TIME FACTOR; Y CHROMOSOME;

ANIMALS; FEMALE; HEART FUNCTION TESTS; HEART VENTRICLES; HUMANS; MAGNETIC RESONANCE IMAGING; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; PERICARDIAL FLUID; STEM CELL TRANSPLANTATION; STEM CELLS; SUS SCROFA; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TROPONIN; VENTRICULAR REMODELING; Y CHROMOSOME;

EID: 84938966251     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0512-2     Document Type: Article

References (54)

1. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe: epidemiological update. Eur Heart J. 2013;34:3028-34.
2. Dimmeler S, Burchfield J, Zeiher AM. Cell-Based Therapy of Myocardial Infarction. Arterioscler Thromb Vasc Biol. 2008;28:208-16.
3. van der Spoel TIG, Jansen Lorkeers SJ, Agostoni P, Van Belle E, Gyöngyösi M, Sluijter JPG, et al. Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease. Cardiovasc Res. 2011;91:649-58.
4. Ellison GM, Torella D, Dellegrottaglie S, Perez-Martinez C, Perez De Prado A, Vicinanza C, et al. Endogenous Cardiac Stem Cell Activation by Insulin-Like Growth Factor-1/Hepatocyte Growth Factor Intracoronary Injection Fosters Survival and Regeneration of the Infarcted Pig Heart. J Am Coll Cardiol. 2011;58:977-86.
5. Malliaras K, Smith RR, Kanazawa H, Yee K, Seinfeld J, Tseliou E, et al. Validation of Contrast-Enhanced MRI to Monitor Regenerative Efficacy after Cell Therapy in a Porcine Model of Convalescent Myocardial Infarction. Circulation. 2013;128:2764-75.
6. Johnston PV, Sasano T, Mills K, Evers R, Lee ST, Smith RR, et al. Engraftment, differentiation, and functional benefits of autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy. Circulation. 2009;120:1075-83. 1077 p following 1083.
7. Malliaras K, Li TS, Luthringer D, Terrovitis J, Cheng K, Chakravarty T, et al. Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells. Circulation. 2012;125:100-12.
8. Welt FGP, Gallegos R, Connell J, Kajstura J, D'Amario D, Kwong RY, et al. Effect of cardiac stem cells on left-ventricular remodeling in a canine model of chronic myocardial infarction. Circulation Heart Failure. 2013;6:99-106.
9. Li R-K, Mickle DAG, Weisel RD, Rao V, Jia Z-Q. Optimal time for cardiomyocyte transplantation to maximize myocardial function after left ventricular injury. Ann Thorac Surg. 2001;72:1957-63.
10. Bolli R, Tang X-L, Sanganalmath SK, Rimoldi O, Mosna F, Abdel-Latif A, et al. Intracoronary delivery of autologous cardiac stem cells improves cardiac function in a porcine model of chronic ischemic cardiomyopathy. Circulation. 2013;128:122-31.
11. Tseliou E, Pollan S, Malliaras K, Terrovitis J, Sun B, Galang G, et al. Allogeneic cardiospheres safely boost cardiac function and attenuate adverse remodeling after myocardial infarction in immunologically mismatched Rat strains. J Am Coll Cardiol. 2013;61:1108-19.
12. Dawn B, Stein AB, Urbanek K, Rota M, Whang B, Rastaldo R, et al. Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function. Proc Natl Acad Sci U S A. 2005;102:3766-71.
13. Bolli R, Chugh AR, D'Amario D, Loughran JH, Stoddard MF, Ikram S, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011;378:1847-57.
14. Chugh AR, Beache GM, Loughran JH, Mewton N, Elmore JB, Kajstura J, et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation. 2012;126:S54-64.
15. Malliaras K, Makkar RR, Smith RR, Cheng K, Wu E, Bonow RO, et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence for therapeutic regeneration in the final 1-year results of the CADUCEUS trial. J Am Coll Cardiol. 2014;63:110-22.
16. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LEJ, Berman D, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet. 2012;379:895-904.
17. Richardson JD, Bertaso AG, Psaltis PJ, Frost L, Carbone A, Paton S, et al. Impact of timing and dose of mesenchymal stromal cell therapy in a preclinical model of acute myocardial infarction. J Card Fail. 2013;19:342-53.
18. Gnecchi M, He H, Melo LG, Noiseaux N, Morello F, de Boer RA, et al. Early beneficial effects of bone marrow-derived mesenchymal stem cells overexpressing Akt on cardiac metabolism after myocardial infarction. STEM CELLS. 2009;27:971-9.
19. Freyman T, Polin G, Osman H, Crary J, Lu M, Cheng L, et al. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J. 2006;27:1114-22.
20. Lim SY, Kim YS, Ahn Y, Jeong MH, Hong MH, Joo SY, et al. The effects of mesenchymal stem cells transduced with Akt in a porcine myocardial infarction model. Cardiovasc Res. 2006;70:530-42.
21. Schuleri KH, Amado LC, Boyle AJ, Centola M, Saliaris AP, Gutman MR, et al. Early improvement in cardiac tissue perfusion due to mesenchymal stem cells. Am J Physiol Heart Circ Physiol. 2008;294:H2002-11.
22. Kanazawa H, Malliaras K, Yee K, Dawkins J, Tseliou E, Marbán L, Makkar R, Marban E. Cardioprotective effect of allogeneic cardiosphere-derived cells: reduction of infarct size and attenuation of no-reflow when administered in the infarct-related artery after reperfusion in pigs with acute myocardial infarction. J Am Coll Cardiol. 2013; 61.
23. Kanazawa H, Malliaras K, Yee K, Dawkins J, Tseliou E, Marban L, Makkar R, Marban E. Allogeneic cardiosphere-derived cells after reperfusion are effective in reducing infarct size and attenuatting adverse remodelling in pigs with acute myocardial infarction. J Am Coll Cardiol. 2013l; 61.
24. Houtgraaf JH, de Jong R, Kazemi K, de Groot D, van der Spoel TI, Arslan F, et al. Intracoronary infusion of allogeneic mesenchymal precursor cells directly after experimental acute myocardial infarction reduces infarct size, abrogates adverse remodeling, and improves cardiac function. Circ Res. 2013;113:153-66.
25. Crisostomo V, Casado JG, Baez-Diaz C, Blazquez R, Sanchez-Margallo FM. Allogeneic cardiac stem cell administration for acute myocardial infarction. Expert Rev Cardiovasc Ther. 2015;13:285-99.
26. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res. 2008;103:1204-19.
27. Kubal C, Sheth K, Nadal-Ginard B, Galiñanes M. Bone marrow cells have a potent anti-ischemic effect against myocardial cell death in humans. J Thorac Cardiovasc Surg. 2006;132:1112-8.
28. Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Hölschermann H, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006;355:1210-21.
29. Bartunek J, Wijns W, Heyndrickx GR, Vanderheyden M. Timing of intracoronary bone-marrow-derived stem cell transplantation after ST-elevation myocardial infarction. Nat Clin Pract Cardiovasc Med. 2006;3(Suppl1):S52-56.
30. Heldman AW, DiFede DL, Fishman JE, Zambrano JP, Trachtenberg BH, Karantalis V, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: The tac-hft randomized trial. JAMA. 2014;311:62-73.
31. Williams AR, Hatzistergos KE, Addicott B, McCall F, Carvalho D, Suncion V, et al. Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. Circulation. 2013;127:213-23.
32. Kelley KW, Curtis SE, Marzan GT, Karara HM, Anderson CR. Body surface area of female swine. J Anim Sci. 1973;36:927-30.
33. Lauden L, Boukouaci W, Borlado LR, López IP, Sepúlveda P, Tamouza R, et al. Allogenicity of human cardiac stem/progenitor cells orchestrated by programmed death ligand 1. Circ Res. 2013;112:451-64.
34. de Silva R, Raval AN, Hadi M, Gildea KM, Bonifacino AC, Yu Z-X, et al. Intracoronary infusion of autologous mononuclear cells from bone marrow or granulocyte colony-stimulating factor-mobilized apheresis product may not improve remodelling, contractile function, perfusion, or infarct size in a swine model of large myocardial infarction. Eur Heart J. 2008;29:1772-82.
35. Dubois C, Liu X, Claus P, Marsboom G, Pokreisz P, Vandenwijngaert S, et al. Differential effects of progenitor cell populations on left ventricular remodeling and myocardial neovascularization after myocardial infarction. J Am Coll Cardiol. 2010;55:2232-43.
36. Crisostomo VBC, Maestre J, Casado JG, Rosado R, Sanchez B, Abad JL, et al. Safety of allogeneic pCSCs intracoronary delivery: a pathological and MR study assessment in the porcine model. Hum Gene Ther. 2013;24:A114.
37. Karantalis V, Schulman IH, Balkan W, Hare JM. Allogeneic cell therapy: a New paradigm in therapeutics. Circ Res. 2015;116:12-5.
38. Jansen Lorkeers SJ, Eding JEC, Vesterinen HM, Van Der Spoel TIG, Sena ES, Duckers HJ, et al. Similar effect of autologous and allogeneic cell therapy for ischemic heart disease: systematic review and meta-analysis of large animal studies. Circ Res. 2015;116:80-6.
39. Quevedo HC, Hatzistergos KE, Oskouei BN, Feigenbaum GS, Rodriguez JE, Valdes D, et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci. 2009;106:14022-7.
40. Schuleri KH, Feigenbaum GS, Centola M, Weiss ES, Zimmet JM, Turney J, et al. Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy. Eur Heart J. 2009;30:2722-32.
41. Kukielka GL, Smith CW, Manning AM, Youker KA, Michael LH, Entman ML. Induction of interleukin-6 synthesis in the myocardium: potential role in postreperfusion inflammatory injury. Circulation. 1995;92:1866-75.
42. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236-41.
43. Irwin MW, Mak S, Mann DL, Qu R, Penninger JM, Yan A, et al. Tissue expression and immunolocalization of tumor necrosis factor-aα in postinfarction dysfunctional myocardium. Circulation. 1999;99:1492-8.
44. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E, et al. Elevation of tumor necrosis factor-aα and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101:2149-53.
45. Bujak M, Frangogiannis NG. The role of TGF-β signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res. 2007;74:184-95.
46. Redondo S, Navarro-Dorado J, Ramajo M, Medina U, Tejerina T. The complex regulation of TGF-beta in cardiovascular disease. Vasc Health Risk Manag. 2012;8:533-9.
47. Wang Y, Hu X, Xie X, He A, Liu X, Wang JA. Effects of mesenchymal stem cells on matrix metalloproteinase synthesis in cardiac fibroblasts. Exp Biol Med. 2011;236:1197-204.
48. Ellison G, Nadal-Ginard B, Torella D. Optimizing cardiac repair and regeneration through activation of the endogenous cardiac stem cell compartment. J Cardiovasc Transl Res. 2012;5:667-77.
49. Leri A, Kajstura J, Anversa P. Cardiac stem cells and mechanisms of myocardial regeneration. Physiol Rev. 2005;85:1373-416.
50. Chimenti I, Smith RR, Li T-S, Gerstenblith G, Messina E, Giacomello A, et al. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ Res. 2010;106:971-80.
51. Ellison GM, Torella D, Trigueros C, Gonzalez AC, Waring C, Perez Martinez A, et al. Use of heterologous non-matched Cardiac Stem Cells (CSCs) without immunosuppression as an effective regenerating agent in a porcine model of acute myocardial infarction. Eur Heart J. 2009;30:495.
52. Yang Y-J, Qian H-Y, Huang J, Li J-J, Gao R-L, Dou K-F, et al. Combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells increases benefits in infarcted swine hearts. Arterioscler Thromb Vasc Biol. 2009;29:2076-82.
53. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987;76:44-51.
54. Crisostomo V, Maestre J, Maynar M, Sun F, Baez-Diaz C, Uson J, et al. Development of a closed chest model of chronic myocardial infarction in swine: magnetic resonance imaging and pathological evaluation. ISRN Cardiol. 2013;2013:781762.